Research Analysts Offer Predictions for AURA FY2030 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – Stock analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Aura Biosciences in a research report issued on Monday, March 30th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.35) for the year. HC Wainwright currently has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Aura Biosciences in a research note on Friday, March 27th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $20.50.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $6.54 on Thursday. The stock has a market capitalization of $419.54 million, a P/E ratio of -3.65 and a beta of 0.35. The company has a 50 day moving average price of $5.92 and a 200 day moving average price of $5.87. Aura Biosciences has a fifty-two week low of $4.34 and a fifty-two week high of $7.48.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Monday, March 30th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06.

Institutional Investors Weigh In On Aura Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Permanent Capital Management LP purchased a new position in Aura Biosciences in the third quarter valued at $913,000. B Group Inc. raised its stake in Aura Biosciences by 21.2% in the second quarter. B Group Inc. now owns 572,576 shares of the company’s stock valued at $3,584,000 after buying an additional 100,000 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Aura Biosciences during the 2nd quarter worth about $31,926,000. Resolute Capital Asset Partners LLC acquired a new position in shares of Aura Biosciences during the 2nd quarter worth about $570,000. Finally, Levin Capital Strategies L.P. boosted its position in shares of Aura Biosciences by 8.8% during the 3rd quarter. Levin Capital Strategies L.P. now owns 1,627,274 shares of the company’s stock worth $10,057,000 after acquiring an additional 131,714 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Amy Elazzouzi sold 8,549 shares of Aura Biosciences stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $5.06, for a total value of $43,257.94. Following the completion of the transaction, the senior vice president owned 75,532 shares in the company, valued at approximately $382,191.92. This trade represents a 10.17% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Conor Kilroy sold 12,079 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $5.05, for a total transaction of $60,998.95. Following the sale, the insider owned 167,234 shares in the company, valued at $844,531.70. The trade was a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 123,076 shares of company stock worth $618,783 over the last ninety days. Company insiders own 6.30% of the company’s stock.

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.